nach oben

Drugs

Erschienen in:

01.04.2019 | AdisInsight Report

Toripalimab: First Global Approval

verfasst von: Susan J. Keam

Erschienen in: Drugs | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers. In December 2018, based on positive efficacy results of a phase 2 trial and safety data from several clinical studies, toripalimab received conditional approval in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy. This article summarizes the milestones in the development of toripalimab leading to this first global approval for the treatment of unresectable or metastatic melanoma.

National Medical Products Administration. The first domestic PD-1 antibody drug, treipril monoclonal antibody injection, was approved for marketing [media release]. 17 Dec 2018.

Shanghai Junshi Biosciences Co. Ltd. China’s first self-developed PD-1 monoclonal antibody, Treripril monoclonal antibody, was approved for marketing, and Junshi Biotechnology promoted China’s accelerated entry into a new era of tumor immunotherapy [media release]. 17 Dec 2018. http://junshipharma.com/News.html.

Fu J, Wang F, Dong LH, et al. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin. 2017;38(5):710–8.CrossRefPubMedPubMedCentral

Shanghai Junshi Biosciences Co. Ltd. Therapeutic areas: immuno-oncology: JS001 (toripalimab, anti-PD-1 mAb); 2019. http://www.junshipharma.com/en/Treatment.html. Accessed 9 Jan 2019.

Shanghai Junshi Bioscience Co. Ltd. Toripalimab monoclonal antibody injection: Chinese prescribing information; 2019.

Hogan Lovells. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs [media release]. 17 Jan 2018. https://www.lexology.com/library/detail.aspx?g=73ce9342-8178-4b42-9c31-389edf0278c1.

Chi Z, Tang B, Sheng X, et al. A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China [abstract no. 9539]. J Clin Oncol. 2018;36(15 Suppl.).

Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012;48(1):94–100.CrossRefPubMed

Hutchison China MediTech Ltd. Chi-Med enters into multiple collaborations to evaluate combinations of surufatinib and fruquintinib with PD-1 checkpoint inhibitors [media release]. 29 Nov 2018.

10.

CSPC Pharmaceutical Group Ltd. Product co-development and strategic collaboration agreement [media release]. 10 Jul 2018.

11.

Shanghai Junshi Biosciences. Shanghai Junshi Biosciences Co., Ltd global offering; 2018. http://www.junshipharma.com/en/Investor-314.html. Accessed 21 Jan 2019.

12.

Tang B, Yan X, Sheng X, et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019;12(1):7.CrossRefPubMedPubMedCentral

13.

Wang FH, Ren C, Zhang Y, et al. Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors [abstract no. 1186P]. Ann Oncol. 2017;28(Suppl. 5):v420–1.

14.

Guo J, Sheng X, Si L, et al. A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma [abstract no. 9528]. J Clin Oncol. 2018;36(15 Suppl.).

15.

Xu R, Wang FH, Feng FJ, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: preliminary results of an open-label phase II clinical study [abstract no. 1150P]. Ann Oncol. 2018;29(Suppl. 8):viii409.

16.

Sheng X, Chi Z, Cui C, et al. Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody [abstract no. e16505]. J Clin Oncol. 2018;36(15 Suppl.).

17.

Xu RH, Wang F, Shi J, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: preliminary results of an open-label, multi-cohort, phase Ib/II clinical study [abstract no. 116]. J Clin Oncol. 2018;36(4 Suppl.).

18.

Xu RH, Wang F, Xu N, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: preliminary results of an open-label, multi-cohort, phase Ib/II clinical study [abstract no. 108]. J Clin Oncol. 2018;36(4 Suppl.).

19.

Bian L, Zhang H, Wang T, et al. A phase I study of JS001, a humanized PD-1mAb in patients with advanced triple negative breast cancer [abstract no. e15093]. J Clin Oncol. 2018;36(15 Suppl.).

20.

Yang S, Yang J, Han X, et al. Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: results from a phase 1 trial [abstract no. 11572]. J Clin Oncol. 2018;36(15 Suppl.).

21.

Zhang P, Lu M, Li J. Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase Ib trial [abstract no. 1309O]. Ann Oncol. 2018;29(Suppl. 8):viii468.

Titel: Toripalimab: First Global Approval
verfasst von: Susan J. Keam
Publikationsdatum: 01.04.2019
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 5/2019
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-019-01076-2

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Toripalimab: First Global Approval

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Correction to: Fremanezumab: First Global Approval

Correction to: Tapentadol Prolonged Release: A Review in Pain Management

Correction to: Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee

Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches

Correction to: Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia

Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy